London Daily

Focus on the big picture.
Thursday, Nov 20, 2025

Austria and Denmark plan vaccines with Israel to bolster slow EU supply

Austria and Denmark plan vaccines with Israel to bolster slow EU supply

Austria and Denmark, chafing at the slow rollout of COVID-19 vaccines within the European Union, have joined forces with Israel to produce second-generation vaccines against mutations of the coronavirus.

The move by the two EU member states comes amid rising anger over delays in ordering, approving and distributing vaccines that have left the 27-member bloc trailing far behind Israel’s world-beating vaccination campaign.

Austrian Chancellor Sebastian Kurz said it was right that the EU procures vaccines for its member states but the European Medicines Agency (EMA) had been too slow to approve them and lambasted pharmaceutical companies’ supply bottlenecks.

“We must therefore prepare for further mutations and should no longer be dependent only on the EU for the production of second-generation vaccines,” the conservative chancellor said in a statement on Tuesday.

Danish Prime Minister Danish Mette Frederiksen was also critical of the EU’s vaccine programme.

“I don’t think it can stand alone, because we need to increase capacity. That is why we are now fortunate to start a partnership with Israel,” she told reporters on Monday.

When asked whether Denmark and Austria wanted to take unilateral action in obtaining vaccines, Frederiksen said: “You can call it that.”

The European Commission said member states were free to strike separate deals should they wish to. “It’s not that the strategy unravelled or it goes against the strategy, not at all,” spokesman Stefan de Keersmaecker said.

An EMA spokeswoman did not have an immediate comment.

FIRST MOVERS?


Kurz and Frederiksen are due to travel to Israel this week to see Israel’s rapid vaccine roll-out up close.

Israel, which was quick to sign contracts for and to approve vaccines from U.S. drug makers Pfizer and Moderna, has given 94 doses per 100 people and the EU just seven, according to monitoring by Our World in Data.

Prime Minister Benjamin Netanyahu, who has made the campaign a showcase of his bid for re-election on March 23, has spoken of “an international corporation for manufacturing vaccines”.

None of the three countries has significant vaccine making capacity, however, raising questions over how realistic their ambitions are to gain greater self-sufficiency.

A growing number of EU countries have placed side orders for vaccines from Russia and China, even though the EMA has yet to rule on whether they are both safe and effective.

Slovakia said on Monday it had ordered 2 million doses of Russia’s Sputnik V vaccine and expects half to arrive this month to help it end a surge in infections.

The neighbouring Czech Republic - tackling the worst COVID-19 outbreak of any EU country - is also considering ordering Russia’s Sputnik V.

Hungary, meanwhile, has taken delivery of a vaccine developed by China’s Sinopharm, with Prime Minister Viktor Orban announcing on Sunday that he had received the shot.

The three vaccines so far cleared for use in the EU, made by Pfizer and German partner BioNTech, Moderna and AstraZeneca, rely on production in countries including Germany, Britain, Switzerland, Belgium and the Netherlands.

Kurz said Austria and Denmark would work with Israel on vaccine production against mutations of the coronavirus and jointly research treatment options in an alliance called the First Movers Group.

The initiative, which seeks greater protection against future pandemics in addition to joint EU vaccine supply, follows Germany’s decision last month to set up a task force to address supply bottlenecks and boost local manufacturing.

Kurz invited pharmaceutical companies with a local presence including Pfizer, Valneva, Novartis, Polymun and Boehringer Ingelheim on Tuesday to discuss the new initiative.

Pfizer, which declined comment for this story, has said it will make 2 billion doses this year - 70% of them in the EU - and has conducted extensive research into their effectiveness against coronavirus variants.

A spokesman for Boehringer Ingelheim said its focus was not on human vaccines “but if we receive requests we will of course look into them.”

Newsletter

Related Articles

0:00
0:00
Close
Trump and Mamdani to Meet at the White House: “The Communist Asked”
Nvidia Again Beats Forecasts, Shares Jump in After-Hours Trading
Wintry Conditions Persist Along UK Coasts After Up to Seven Centimetres of Snow
UK Inflation Eases to 3.6 % in October, Opening Door for Rate Cut
UK Accelerates Munitions Factory Build-Out to Reinforce Warfighting Readiness
UK Consumer Optimism Plunges Ahead of November Budget
A Decade of Innovation Stagnation at Apple: The Cook Era Critique
Caribbean Reparations Commission Seeks ‘Mutually Beneficial’ Justice from UK
EU Insists UK Must Contribute Financially for Access to Electricity Market and Broader Ties
UK to Outlaw Live-Event Ticket Resales Above Face Value
President Donald Trump Hosts Saudi Crown Prince Mohammed bin Salman at White House to Seal Major Defence and Investment Deals
German Entertainment Icons Alice and Ellen Kessler Die Together at Age 89
UK Unveils Sweeping Asylum Reforms with 20-Year Settlement Wait and Conditional Status
UK Orders Twitter Hacker to Repay £4.1 Million Following 2020 High-Profile Breach
Popeyes UK Eyes Century Mark as Fried-Chicken Chain Accelerates Roll-out
Two-thirds of UK nurses report working while unwell amid staffing crisis
Britain to Reform Human-Rights Laws in Sweeping Asylum Policy Overhaul
Nearly Half of Job Losses Under Labour Government Affect UK Youth
UK Chancellor Reeves Eyes High-Value Home Levy in Budget to Raise Tens of Billions
UK Urges Poland to Choose Swedish Submarines in Multi-Billion € Defence Bid
US Border Czar Tom Homan Declares UK No Longer a ‘Friend’ Amid Intelligence Rift
UK Announces Reversal of Income Tax Hike Plans Ahead of Budget
Starmer Faces Mounting Turmoil as Leaked Briefings Ignite Leadership Plot Rumours
UK Commentator Sami Hamdi Returns Home After US Visa Revocation and Detention
UK Eyes Denmark-Style Asylum Rules in Major Migration Shift
UK Signals Intelligence Freeze Amid US Maritime Drug-Strike Campaign
TikTok Awards UK & Ireland 2025 Celebrates Top Creators Including Max Klymenko as Creator of the Year
UK Growth Nearly Stalls at 0.1% in Q3 as Cyberattack Halts Car Production
Apple Denied Permission to Appeal UK App Store Ruling, Faces Over £1bn Liability
UK Chooses Wylfa for First Small Modular Reactors, Drawing Sharp U.S. Objection
Starmer Faces Growing Labour Backlash as Briefing Sparks Authority Crisis
Reform UK Withdraws from BBC Documentary Amid Legal Storm Over Trump Speech Edit
UK Prime Minister Attempts to Reassert Authority Amid Internal Labour Leadership Drama
UK Upholds Firm Rules on Stablecoins to Shield Financial System
Brussels Divided as UK-EU Reset Stalls Over Budget Access
Prince Harry’s Remembrance Day Essay Expresses Strong Regret at Leaving Britain
UK Unemployment Hits 5% as Wage Growth Slows, Paving Way for Bank of England Rate Cut
Starmer Warns of Resurgent Racism in UK Politics as He Vows Child-Poverty Reforms
UK Grocery Inflation Slows to 4.7% as Supermarkets Launch Pre-Christmas Promotions
UK Government Backs the BBC amid Editing Scandal and Trump Threat of Legal Action
UK Assessment Mis-Estimated Fallout From Palestine Action Ban, Records Reveal
UK Halts Intelligence Sharing with US Amid Lethal Boat-Strike Concerns
King Charles III Leads Britain in Remembrance Sunday Tribute to War Dead
UK Retail Sales Growth Slows as Households Hold Back Ahead of Black Friday and Budget
Shell Pulls Out of Two UK Floating Wind Projects Amid Renewables Retreat
Viagogo Hit With £15 Million Tax Bill After HMRC Transfer-Pricing Inquiry
Jaguar Land Rover Cyberattack Pinches UK GDP, Bank of England Says
UK and Germany Sound Alarm on Russian-Satellite Threat to Critical Infrastructure
Former Prince Andrew Faces U.S. Congressional Request for Testimony Amid Brexit of Royal Title
BBC Director-General Tim Davie and News CEO Deborah Turness Resign Amid Editing Controversy
×